NASDAQ:MTVA MetaVia (MTVA) Stock Price, News & Analysis $1.48 +0.06 (+4.23%) Closing price 08/3/2026 04:00 PM EasternExtended Trading$1.50 +0.02 (+1.15%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About MetaVia Stock (NASDAQ:MTVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MetaVia alerts:Sign Up Key Stats Today's Range$1.45▼$1.5650-Day Range$1.42▼$3.3452-Week Range$0.97▼$19.03Volume34,803 shsAverage Volume572,228 shsMarket Capitalization$7.64 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Read More MetaVia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreMTVA MarketRank™: MetaVia scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMetaVia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialMetaVia has a consensus price target of $20.00, representing about 1,251.4% upside from its current price of $1.48.Amount of Analyst CoverageMetaVia has only been the subject of 2 research reports in the past 90 days.Read more about MetaVia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MetaVia are expected to decrease in the coming year, from ($2.78) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MetaVia is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MetaVia is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMetaVia has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MetaVia's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.71% of the float of MetaVia has been sold short.Short Interest Ratio / Days to CoverMetaVia has a short interest ratio ("days to cover") of 0.33, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MetaVia has recently increased by 177.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetaVia does not currently pay a dividend.Dividend GrowthMetaVia does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added MetaVia to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MetaVia insiders have not sold or bought any company stock.Percentage Held by Insiders0.60% of the stock of MetaVia is held by insiders.Percentage Held by Institutions1.37% of the stock of MetaVia is held by institutions.Read more about MetaVia's insider trading history. Receive MTVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTVA Stock News HeadlinesMetaVia Inc.: MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of ObesityJuly 9, 2026 | finanznachrichten.deMetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of ObesityJuly 9, 2026 | prnewswire.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead. | Stansberry Research (Ad)MetaVia Announces $4 Million At-The-Market Stock OfferingJuly 2, 2026 | tipranks.comMTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific SessionsJune 17, 2026 | finance.yahoo.comMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor ForumJune 17, 2026 | prnewswire.comBioStem Technologies Announces Appointment of Three New Members to its Board of DirectorsJune 9, 2026 | globenewswire.comMetaVia Shareholders Approve Equity Plan and Reverse SplitJune 8, 2026 | tipranks.comSee More Headlines MTVA Stock Analysis - Frequently Asked Questions How have MTVA shares performed this year? MetaVia's stock was trading at $8.42 at the beginning of the year. Since then, MTVA stock has decreased by 82.4% and is now trading at $1.48. How were MetaVia's earnings last quarter? MetaVia Inc. (NASDAQ:MTVA) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.03. When did MetaVia's stock split? MetaVia shares reverse split before market open on Friday, December 5th 2025.The 1-11 reverse split was announced on Tuesday, December 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did MetaVia IPO? MetaVia (MTVA) raised $36 million in an initial public offering (IPO) on Thursday, June 23rd 2016. The company issued 3,000,000 shares at $11.00-$13.00 per share. How do I buy shares of MetaVia? Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today8/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 MTVA's financial health is in the Yellow zone, according to TradeSmith. MTVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MTVA Previous SymbolNASDAQ:NRBO CIK1638287 Webwww.neurobopharma.com Phone857-702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Price Target for MetaVia$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+1,251.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-172.92% Return on Assets-89.39% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.64Miscellaneous Outstanding Shares5,160,000Free Float5,133,000Market Cap$7.64 million OptionableN/A Beta0.95 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:MTVA) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
